An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome.
Adult-onset still?s disease
Anti-complement factor H antibodies
Atypical haemolytic syndrome
Macrophage activation syndrome
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
22
12
2023
accepted:
15
03
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
Atypical haemolytic uremic syndrome (aHUS) is an uncommon form of thrombotic microangiopathy (TMA). However, it remains difficult to diagnose the disease early, given its non-specific and overlapping presentation to other conditions such as thrombotic thrombocytopenic purpura and typical HUS. It is also important to identify the underlying causes and to distinguish between primary (due to a genetic abnormality leading to a dysregulated alternative complement pathway) and secondary (often attributed by severe infection or inflammation) forms of the disease, as there is now effective treatment such as monoclonal antibodies against C5 for primary aHUS. However, primary aHUS with severe inflammation are often mistaken as a secondary HUS. We presented an unusual case of adult-onset Still's disease (AOSD) with macrophage activation syndrome (MAS), which is in fact associated with anti-complement factor H (anti-CFH) antibodies related aHUS. Although the aHUS may be triggered by the severe inflammation from the AOSD, the presence of anti-CFH antibodies suggests an underlying genetic defect in the alternative complement pathway, predisposing to primary aHUS. One should note that anti-CFH antibodies associated aHUS may not always associate with genetic predisposition to complement dysregulation and can be an autoimmune form of aHUS, highlighting the importance of genetic testing. A 42 years old man was admitted with suspected adult-onset Still's disease. Intravenous methylprednisolone was started but patient was complicated with acute encephalopathy and low platelet. ADAMTS13 test returned to be normal and concurrent aHUS was eventually suspected, 26 days after the initial thrombocytopenia was presented. Plasma exchange was started and patient eventually had 2 doses of eculizumab after funding was approved. Concurrent tocilizumab was also used to treat the adult-onset Still's disease with MAS. The patient was eventually stabilised and long-term tocilizumab maintenance treatment was planned instead of eculizumab following haematology review. Although the aHUS may be a secondary event to MAS according to haematology opinion and the genetic test came back negative for the five major aHUS gene, high titre of anti-CFH antibodies was detected (1242 AU/ml). Our case highlighted the importance of prompt anti-CFH antibodies test and genetic testing for aHUS in patients with severe AOSD and features of TMA. Our case also emphasized testing for structural variants within the CFH and CFH-related proteins gene region, as part of the routine genetic analysis in patients with anti-CFH antibodies associated aHUS to improve diagnostic approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Atypical haemolytic uremic syndrome (aHUS) is an uncommon form of thrombotic microangiopathy (TMA). However, it remains difficult to diagnose the disease early, given its non-specific and overlapping presentation to other conditions such as thrombotic thrombocytopenic purpura and typical HUS. It is also important to identify the underlying causes and to distinguish between primary (due to a genetic abnormality leading to a dysregulated alternative complement pathway) and secondary (often attributed by severe infection or inflammation) forms of the disease, as there is now effective treatment such as monoclonal antibodies against C5 for primary aHUS. However, primary aHUS with severe inflammation are often mistaken as a secondary HUS. We presented an unusual case of adult-onset Still's disease (AOSD) with macrophage activation syndrome (MAS), which is in fact associated with anti-complement factor H (anti-CFH) antibodies related aHUS. Although the aHUS may be triggered by the severe inflammation from the AOSD, the presence of anti-CFH antibodies suggests an underlying genetic defect in the alternative complement pathway, predisposing to primary aHUS. One should note that anti-CFH antibodies associated aHUS may not always associate with genetic predisposition to complement dysregulation and can be an autoimmune form of aHUS, highlighting the importance of genetic testing.
CASE PRESENTATION
METHODS
A 42 years old man was admitted with suspected adult-onset Still's disease. Intravenous methylprednisolone was started but patient was complicated with acute encephalopathy and low platelet. ADAMTS13 test returned to be normal and concurrent aHUS was eventually suspected, 26 days after the initial thrombocytopenia was presented. Plasma exchange was started and patient eventually had 2 doses of eculizumab after funding was approved. Concurrent tocilizumab was also used to treat the adult-onset Still's disease with MAS. The patient was eventually stabilised and long-term tocilizumab maintenance treatment was planned instead of eculizumab following haematology review. Although the aHUS may be a secondary event to MAS according to haematology opinion and the genetic test came back negative for the five major aHUS gene, high titre of anti-CFH antibodies was detected (1242 AU/ml).
CONCLUSION
CONCLUSIONS
Our case highlighted the importance of prompt anti-CFH antibodies test and genetic testing for aHUS in patients with severe AOSD and features of TMA. Our case also emphasized testing for structural variants within the CFH and CFH-related proteins gene region, as part of the routine genetic analysis in patients with anti-CFH antibodies associated aHUS to improve diagnostic approaches.
Identifiants
pubmed: 38745129
doi: 10.1186/s12882-024-03548-4
pii: 10.1186/s12882-024-03548-4
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
164Informations de copyright
© 2024. The Author(s).
Références
Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508–30. https://doi.org/10.1016/j.semnephrol.2013.08.003 .
doi: 10.1016/j.semnephrol.2013.08.003
pubmed: 24161037
pmcid: 3863953
Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematol Am Soc Hematol Educ Program. 2016;2016(1):217–25. https://doi.org/10.1182/asheducation-2016.1.217 .
doi: 10.1182/asheducation-2016.1.217
Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(2):555–63. https://doi.org/10.1681/ASN.2004050380 .
doi: 10.1681/ASN.2004050380
pubmed: 15590760
Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379–87. https://doi.org/10.1182/blood-2009-05-221549 .
doi: 10.1182/blood-2009-05-221549
pubmed: 19861685
pmcid: 2829859
https:// www.centogene.com/diagnostics/our-tests/ngs-panels/nephrology . Assessed on 16/2/2024.
Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ, Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–551. https://doi.org/10.1016/j.kint.2016.10.005 .
Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A. Clinical and Immunological Profile of anti-factor H antibody Associated atypical hemolytic uremic syndrome: a Nationwide Database. Front Immunol. 2019;10:1282. https://doi.org/10.3389/fimmu.2019.01282 .
doi: 10.3389/fimmu.2019.01282
pubmed: 31231391
pmcid: 6567923
Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21(12):2180–7. https://doi.org/10.1681/ASN.2010030315 .
doi: 10.1681/ASN.2010030315
pubmed: 21051740
pmcid: 3014031
Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood. 2007;110(5):1516–8. https://doi.org/10.1182/blood-2007-02-071472 .
doi: 10.1182/blood-2007-02-071472
pubmed: 17495132
Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T, German-Austrian HUS Study Group. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2013;8(3):407–15. https://doi.org/10.2215/CJN.01260212 .
doi: 10.2215/CJN.01260212
pubmed: 23243267
Gao Q, Yuan Y, Wang Y, Jiang J, Ye Z, Liu T, Jiang Z, Zhao L. Clinical characteristics of macrophage activation syndrome in adult-onset Still’s disease. Clin Exp Rheumatol 2021 Sep-Oct;39 Suppl 132(5):59–66. https://doi.org/10.55563/clinexprheumatol/lp2u7g .
Khattab A, Yellala A, Mamadgi J, Patruni S, Kaplan R. Aggressive Disease and Rare Sequelae in a unique case of atypical hemolytic uremic syndrome secondary to adult onset still’s disease. J Hematol. 2019;8(2):64–7. https://doi.org/10.14740/jh491 .
doi: 10.14740/jh491
pubmed: 32300446
pmcid: 7153680
Dillemans L, Bekhuis Y, Betrains A, Yu K, van Hemelen M, Pörtner N, De Somer L, Matthys P, Breckpot J, Tousseyn T, Peetermans M, Proost P, Wouters C, Vanderschueren S. Biallelic mutations in the CFHR genes underlying atypical hemolytic uremic syndrome in a patient with catastrophic adult-onset still’s disease and recurrent macrophage activation syndrome: a case report. Clin Immunol. 2023;257:109815. https://doi.org/10.1016/j.clim.2023.109815 .
doi: 10.1016/j.clim.2023.109815
pubmed: 37898413
Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, Gafter-Gvili A. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail. 2014;36(7):1119–21. https://doi.org/10.3109/0886022X.2014.917574 .
doi: 10.3109/0886022X.2014.917574
pubmed: 24828571
Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4–21. https://doi.org/10.1111/1744-9987.12763 .
doi: 10.1111/1744-9987.12763
pubmed: 30294946
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux-Bacchi V. Global aHUS Registry. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408–18. https://doi.org/10.1016/j.kint.2018.02.029 .
doi: 10.1016/j.kint.2018.02.029
pubmed: 29907460
Kise T, Fukuyama S, Uehara M. Successful treatment of Anti-factor H antibody-Associated atypical hemolytic uremic syndrome. Indian J Nephrol. 2020 Jan-Feb;30(1):35–8. https://doi.org/10.4103/ijn.IJN_336_18 .
Sadiq S, Urisman A, Cil O. Case report: short-term eculizumab use in atypical HUS associated with Lemierre’s syndrome and post-infectious glomerulonephritis. Front Med (Lausanne). 2023;10:1167806. https://doi.org/10.3389/fmed.2023.1167806 .
doi: 10.3389/fmed.2023.1167806
pubmed: 37206472
Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016;12(9):563–78. https://doi.org/10.1038/nrneph.2016.99 .
doi: 10.1038/nrneph.2016.99
pubmed: 27452363